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Origin of the TTC values for compounds that are genotoxic and/or 1 
carcinogenic and an approach for their revaluation 2 
The threshold of toxicological concern (TTC) approach is a resource-effective de 3 
minimismethod for the safety assessment of chemicals, based on distributional 4 
analysis of the results of a large number of toxicological studies. It is being 5 
increasingly used to screen and prioritise substances with low exposure for which 6 
there is little or no toxicological information. The first step in the approach is the 7 
identification of substances that may be DNA-reactive mutagens, to which the 8 
lowest TTC value is applied. This TTC value was based on analysis of the cancer 9 
potency database and involved a number of assumptions that no longer reflect the 10 
state-of-the-science and some of which were not as transparent as they could 11 
have been. Hence, review and updating of the database is proposed, using 12 
inclusion and exclusion criteria reflecting current knowledge. A strategy for the 13 
selection of appropriate substances for TTC determination, based on 14 
consideration of weight of evidence for genotoxicity and carcinogenicity is 15 
outlined. Identification of substances that are carcinogenic by a DNA-reactive 16 
mutagenicmode of action and those that clearly act by a non-genotoxic mode of 17 
action will enable the protectiveness to be determined of both the TTC for DNA-18 
reactive mutagenicityand that applied by default to substances that may be 19 
carcinogenic but are unlikely to be DNA-reactive mutagens (i.e. for Cramer class 20 
I-III compounds). Critical to the application of the TTC approach to substances 21 
that are likely to be DNA-reactive mutagens is the reliability of the software tools 22 
used to identify such compounds. Current methods for this task are reviewed and 23 
recommendations made for their application. 24 
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Introduction 1 
The Threshold of Toxicological Concern (TTC) approach is being increasingly used to 2 
screen and prioritise substances with low exposure for higher tier risk assessments (e.g. 3 
see Embry et al. 2014), and is being accepted more widely by regulatory bodies. The 4 
TTC values in use have been derived from analysis of extensive databases of toxicology 5 
studies in animals from which extracted information has been used to derive 6 
quantitative thresholds of low toxicological concern. The concept is pragmatic and has 7 
evolved over a number of years. It represents a major development in the Reduction, 8 
Refinement and Replacement of the use of animals in toxicity testing (3Rs). Beyond 9 
accepting the concept in principle, it is appropriate to regularly review the quantitative 10 
thresholds that have been derived, ensure they are based on the most up to date 11 
information, reflect state-of-the-science principles, and meet quality standards, so that 12 
the quantitative values can be confirmed or, if need be, refined. A thorough review of 13 
the non-cancer TTC values has been published recently (EFSA 2016).  However, other 14 
than concluding that the TTC value for genotoxic carcinogens is sufficiently protective, 15 
no such review of this value has been undertaken. Hence, this paper considers the 16 
historical development of the TTC values for substances that might be carcinogenic, and 17 
provides recommendations on reviewing and updating these values, as necessary. 18 
Role of de minimis approaches in risk assessment 19 
There are a large number of chemicals in use for which there is little or no toxicological 20 
information. This is exacerbated by the ever increasing sensitivity and versatility of 21 
analytical chemistry to detect the presence of natural and manmade substances in our 22 
environment. There is therefore a need for methods that enable the rapid and cost-23 
effective screening of such chemicals to enable their prioritization for further 24 
assessment. Equally, when regulating chemical products such as food contact materials, 1 
drug impurities, food additives, industrial chemicals and consumer products, it is 2 
important that authorities and industry make the most efficient use of time and resources 3 
to focus on those exposures that are of potential concern while giving lower priority to 4 
those considered to be of negligible concern. This can be achieved by defining de 5 
minimis exposure levels representing negligible risk of adverse effects to human health. 6 
One science-based approach for setting de minimis thresholds is to collect 7 
toxicological data on a large group of substances and to apply this knowledge to 8 
untested substances. Frawley (1967) was one of the first to describe such an approach. 9 
He analysed a large number of chronic oral toxicity studies to derive quantitative de 10 
minimis thresholds for dietary exposures to substances migrating from food contact 11 
materials. 12 
Brief history of existing TTC scheme 13 
Following up the work of Fawley, Rulis (1987) concluded that carcinogenicity was the 14 
most sensitive endpoint from exposure to chemicals (this was on the assumption of a 15 
linear non-threshold dose-response relationship for such substances) and proposed the 16 
use of analysis of the carcinogenic potencies of 343 (subsequently updated to 709 by 17 
(Cheeseman et al. 1999) substances from over 3500 experiments in the Carcinogenic 18 
Potency Database (CPDB) (Gold et al. 1984; Gold et al. 1989; Gold et al. 1995; 19 
European Chemicals Agency (ECHA) 2015) to derive a Threshold of Regulation (TOR) 20 
for new food contact substances migrating into food at only minute concentrations, and 21 
with no structural alerts for DNA-reactive mutagenicity. Following further evaluation 22 
(Munro 1990) the US Federal and Drug Administration (FDA) introduced a TOR of 0.5 23 
ppb for such food contact materials (Federal Register 1995). Using the US FDA default 24 
values for combined food and drink consumption of 3 kg per day per person, and 60 kg 25 
body weight (bw), the level of 0.5 ppb corresponds to a daily exposure of 0.025 µg/kg 1 
bw/day or 1.5 µg/person (see section on “FDA TOR and additional thresholds 2 
developed from it”further details). Based on the analyses by Rulis, Munro and others, 3 
this exposure was concluded to present negligible concern to public health, even if the 4 
substance in question were later identified to be a carcinogen. For new substances 5 
migrating below 0.5 ppb into packaged food and for which there are no concerns for 6 
DNA-reactive mutagenicity, US FDA requires no specific toxicity testing and performs 7 
an abbreviated safety assessment focussed mainly on intake assessment. More detail on 8 
the derivation of the carcinogen thresholds is presented in later sections of this 9 
document. In view of the fact that only a fraction of all natural and manmade substances 10 
possess structural alerts for DNA-reactive mutagenicityand are carcinogenic, and that 11 
these could be identified reasonably well based on structural features, attention turned to 12 
whether suitablede minimis thresholds for repeat dose toxicity other than carcinogenesis 13 
could be developed.  14 
Munro and co-workers evaluated the use of TTC for toxicity other than 15 
carcinogenicity (613 substances) (Munro et al. 1996). Information from the most 16 
sensitive species, sex, and toxicological endpoints was recorded to identify the most 17 
conservative No Observed Effect Level (NOEL)1 value for each substance. Structural 18 
information based on an algorithm developed by Cramer and colleagues was used to 19 
broadly group the chemicals (Cramer et al. 1978). This algorithm grouped chemicals 20 
into three structural classes based on a ‘decision tree’ approach that consists of 33 21 
questions each of which is answered by ‘yes’ or ‘no’. Each answer leads to another 22 
question or to a final classification into one of the threeclasses of expected low, medium 23 
                                                 
1. Whilst Munro et al referred to the points of departure used as NOELs, in fact these were  
mostly also No Observed Adverse Effect Levels (NOAELs). 
or high toxicity. Further details on the Cramer classification scheme can be found in 1 
European Food Safety Authority (EFSA,2016). This part of the TTC approach is for 2 
substances that are non-genotoxic, based on the 5th percentile of NO(A)EL frequency 3 
distributions,and assumes a lifetime exposure. 4 
Outline of current TTC scheme 5 
Kroes et al. (2004) undertook further review of the TTC concept with regard to 6 
potentially sensitive endpoints (i.e. for which potency would not be covered by point of 7 
departures (PODs) for systemic toxicity) such as developmental toxicity and 8 
neurotoxicity, and combined the cancer and non-cancer aspects into a tiered approach. 9 
They noted that the threshold of 0.025 µg/kg bw/day (1.5 µg/day) resulting from the 10 
FDA analysis for its TOR was applicable only to substances for which there was an 11 
absence of any indication of DNA-reactive mutagenic potential. In their analysis, Kroes 12 
et al. (2004) concluded that the appropriate value for compounds that were potentially 13 
DNA-reactive mutagens would need to be 10-fold lower, and derived a TTC for such 14 
compounds of 0.0025 µg/kg bw/day (0.15 µg/day) (see section on “Background to 15 
cancer TTC values”for details). The introduction of the 0.0025 µg/kg bw/day threshold 16 
for potentially DNA-reactive mutagenicsubstances rendered the 0.025 µg/kg bw/day tier 17 
originating from the FDA TOR development work redundant within a tiered approach 18 
to TTC. This is depicted in the tiered decision scheme as, for example, laid out by 19 
World Health Organisation (WHO)/EFSA (EFSA 2016) (Figure 1). However, it is 20 
perhaps worth noting that a higher threshold (1.5 µg/person per day) is used for 21 
pharmaceutical impurities that are mutagenic or that are suspected of being mutagenic 22 
(see section on “Thresholds for impurities in pharmaceuticals” below). 23 
The TTC values derived are not applicable to chemicals belonging to a number 24 
of substance classes (referred to “exclusionary categories” in Figure 1) . Inorganic 25 
chemicals, metals and organometallics, organo-silicon compounds, nanomaterials, 1 
radioactive substances, proteins and high molecular weight or poorly characterised 2 
chemicals such as polymers were excluded since they were not represented in the 3 
toxicity databases. Aflatoxin-like, azoxy and N-nitroso-compounds were excluded as 4 
highly potent genotoxic carcinogens, along with polyhalogenateddibenzo-p-dioxins, -5 
dibenzofurans and dioxin like polychlorinated biphenyls (PCBs, potent carcinogens, 6 
bioaccumulative, with very large kinetic differences between experimental animals and 7 
humans); and steroids (potent carcinogens and lack of agreement on dose thresholds), as 8 
explained in more detail in section on “FDA TOR and additional thresholds developed 9 
from it”. Chemicals with these structural characteristics can be easily identified by, for 10 
example, ChemoTyper using the ToxPrints and the TTC category chemotypes 11 
(https://toxprint.org/). 12 
The TTC approach is currently in use to evaluate migrant substances from 13 
packaging materials (Federal Register 1995), flavourings substances in food (Federal 14 
Register 1993; Joint Food and Agriculture Organization of the United Nations 15 
(FAO)/WHO Expert Committee on Food Additives 1996; Munro et al. 1999; WHO 16 
1999; European Commission 2002) non-relevant plant protection product metabolites in 17 
ground water (European Commission 2003), mutagenic impurities in pharmaceutical 18 
preparations (International Conference on Harmonisation (ICH) 2014), and genotoxic 19 
constituents in herbal preparations (European Medicines Agency (EMA) 2008), albeit 20 
with slight variations in its application. The TTC concept has been acknowledged to be 21 
a science-based prioritisation and risk assessment tool by different organisations such as 22 
WHO International Programme on Chemical Safety (IPCS), EFSA, the Scientific 23 
Committees of the EU Commission and Health Canada (Joint FAO/WHO Expert 24 
Committee on Food Additives 1996; EFSA 2012; Scientific Committee on Consumer 25 
Safety (SCCS), Scientific Committee on Health and Environmental Risks (SCHER) 1 
2012; EFSA 2016; SCCS Note for Guidance (NfG) 2016; Health Canada, 2016). 2 
Use of the TTC concept for chemicals with specific data requirements for their 3 
regulatory approval is currently not acceptable as an alternative to a chemical-specific 4 
evaluation by regulatory authorities (EFSA 2016), although future application in the 5 
prioritisation or first tier assessment of such chemicals is possible, as regulatory 6 
authorities explore means to streamline the assessment process. 7 
Background to cancer TTC values 8 
Definitions 9 
Mutagenicity is defined as the induction of permanent transmissible changes in the 10 
amount or structure of the genetic material of cells or organisms (ECHA 2015). This 11 
includes gene mutations, and structural and numerical changes in chromosomes. 12 
Genotoxicity is a broader term and refers to the capability of substances to damage 13 
DNA, for example covalent binding to DNA nucleobases, and/or cellular components 14 
regulating the fidelity of the genome – such as the spindle apparatus, topoisomerases, 15 
DNA repair systems and DNA polymerases – and includes all adverse effects, direct or 16 
indirect, on genetic information. Genotoxicity is not necessarily associated with 17 
mutagenicity. Alterations to the genetic material of cells may occur spontaneously 18 
endogenously or be induced as a result of exposure to ionising or ultraviolet radiation, 19 
or genotoxic substances. In principle, human exposure to substances that are mutagens 20 
may result in increased frequencies of mutations above background. DNA-reactive 21 
mutagens are substances that can react with and modify DNA directly, either as the 22 
parent chemical or in the form of a metabolite. Chemicals are defined as carcinogenic if 23 
they induce tumours, increase tumour incidence and/or malignancy or shorten the time 24 
to tumour occurrence, relative to controls. Genotoxic chemicals that can cause canceras 1 
a result of their genotoxicity are typically referred to as genotoxic carcinogens (see 2 
section on “Assessment of dataset entries” below for further discussion). More 3 
specifically, where this is a consequence of DNA-reactive mutagenicity, such 4 
compounds have been referred to as DNA-reactive mutagenic carcinogens in the present 5 
paper. Non-genotoxic carcinogens exert their carcinogenic effects through other 6 
mechanisms that do not involve direct alterations in DNA, i.e. direct mutation(Adler et 7 
al. 2011). Chemicals can induce cancer by any route of exposure (e.g., when inhaled, 8 
ingested, applied to the skin or injected), but carcinogenic potential and potency may 9 
depend on the conditions of exposure (e.g., route, level, pattern and duration of 10 
exposure) (ECHA 2015). 11 
FDA TOR and additional thresholds developed from it 12 
On the basis that carcinogenicity by genotoxic substances represents the endpoint of 13 
greatest sensitivity and relevance at low dietary exposures of chemicals (assuming a 14 
linear non-threshold dose-response relationship),Rulis (1987) subjected a suitable subset 15 
of bioassay data from the CPDB (Gold et al. 1984; Gold et al. 1989; Gold et al. 1995) to 16 
probabilistic analysis. The objective was to determine a threshold level of dietary 17 
exposure that provides adequate protection from presumptive carcinogenic risk in 18 
excess of a specified target risk, even in the event that a substance was later discovered 19 
to be a carcinogen. The aim was to prioritise new indirect food additives, i.e. migrating 20 
food contact material components, based on exposure, for further toxicological testing. 21 
Rulis (1987) used animal dose-response data from 343 carcinogens tested by the oral 22 
route to derive TD50 values for the substances (the dose that induces tumours in 50% of 23 
dosed animals over the normal lifespan of the species). Corresponding ‘Virtually Safe 24 
Doses’ (VSDs) for 1 in one million lifetime tumour risk level in exposed individuals, 25 
which served as the target risk, were calculated from these values. The resulting 1 
distribution of VSDs describes the relative probability that a randomly selected 2 
carcinogen would present an excess tumour risk greater than 1x10-6 over a lifetime. 3 
Rulis (1987) did not present specific numbers from the distribution, only that at a 4 
human dietary intake of ca. 0.025 µg/kg bw/day (1.5 µg/day based on 60 kg default 5 
body weight), about half of all carcinogens would exceed the 1 x 10-6excess risk level. 6 
Below a dietary intake of 0.0025 µg/kg bw/day (corresponding to combined food and 7 
drink consumption of 3 kg per day containing 0.050 µg/kg food or drink), about 85% of 8 
the carcinogens resulted in less than 1 x 10-6excess lifetime risk, i.e. 0.0025 µg/kg 9 
bw/day roughly represents the 15th percentile of the VSD distribution. 10 
Rulis (1987) also introduced the consideration that these risks were calculated 11 
on the unrealistic assumption that all substances were carcinogens and discusses that 12 
under the still conservative assumption that 20% of all new food contact substances 13 
were carcinogens, the 0.0025 µg/kg bw/day exposure level would result in less than 1 x 14 
10-6excess lifetime risk in 97% of cases. Rulis(1987) further concluded that it would be 15 
reasonable to assume that a new substance used in packaging materials would contact, 16 
at most, 5% of the diet. Hence, a dietary concentration of 50 ppt would correspond to a 17 
migration of 1 ppb from packaging material into food.  18 
The issue of de minimis thresholds for carcinogens was further elaborated at a 19 
workshop organised by the Canadian Centre for Toxicology (Munro 1990), which 20 
addressed potency data for four different subsets of carcinogens from the CPDB 21 
analysed both parametrically and non-parametrically. The probability that an excess 22 
lifetime cancer target risk of 1 x 10-6 or 1 x 10-5 is not exceeded at various exposure 23 
levels was presented, as a function of the percentage of substances presumed to be 24 
carcinogens. Three of the four data subsets, one of which was that reported by Rulis 25 
(1987), resulted in very similar VSD 15th percentiles, whereas one subset of National 1 
Toxicology Program (NTP)-conducted studies resulted in approximately four-fold 2 
greater values. 3 
Overall, the type of data subset and the statistical approach to low dose 4 
extrapolation were reported to be significant factors in determining the risk probability. 5 
However, the choice of percentage of new substances assumed to be carcinogens had 6 
the most impact on a given risk level associated with different dietary exposures. For 7 
example, at a threshold of 0.5 ppb dietary concentration (0.025 µg/kg bw/day  intake), 8 
the probability of not exceeding a 1 x 10-6excess risk is 63% if one assumes that all new 9 
substances are carcinogens, and increases to 96% if one assumes that only 10% of new 10 
substances are carcinogens. This issue was discussed extensively at the workshop, 11 
without resolution. It was noted that of 260 substances tested for carcinogenicity by the 12 
US National Cancer Institute (NCI)/NTP program (Ashby and Tennant 1991; Fung et 13 
al. 1995), many of which are also listed in the CPDB, roughly 50% acted as 14 
carcinogens: it was pointed out, however, that these databases are impacted by a large 15 
selection bias because those substances tested were predominantly already suspected of 16 
being carcinogens, based on structural features or toxicological effects. Indeed, Fung et 17 
al. (1995) reported in their analysis that whilst of 400 substances tested in cancer 18 
bioassays by NCI/NTP, 210 were positive, of these, 181 had been selected for the 19 
testing program based on suspected carcinogenicity, while only 29 positive substances 20 
(7% of 400) had been chosen due to high exposure potential. Another confounding 21 
factor, which was not discussed by the above authors, is that many of the studies used 22 
doses greatly exceeding the Maximum Tolerated Dose (MTD) which probably meant 23 
that some of the tumour findings were secondary to other toxicity – see further 24 
discussion in sectionon“General criteria for the Cancer Potency database”. 25 
Munro (1990) also reported that the workshop participants discussed the 1 
application of structural alerts and genotoxicity data to distinguish between DNA-2 
reactive carcinogens with potential low-dose effects and non-genotoxic carcinogens 3 
demonstrating thresholds. It was suggested that it might be reasonable to set thresholds 4 
for non-genotoxic carcinogens based on classical toxicological criteria rather than on 5 
low-dose extrapolation of tumour data. This was however not addressed in the analyses, 6 
which treated all carcinogens with the same approach of linear extrapolation from the 7 
TD50 to below the VSD. 8 
The FDA based the TOR of 0.5 ppb (corresponding to a default daily intake of 9 
0.025 µg/kg bw/day based on 60 kg body weight and combined food and drink 10 
consumption of 3 kg per day) finally adopted on the need to provide a reasonable 11 
balance between necessary conservatism and practical utility, including analytical 12 
sensitivity. The TOR applies only to substances used in food-contact articles (Federal 13 
Register 1995) and defines a migration level below which new food contact substances 14 
qualify for an abbreviated approval process, provided that no concern exists for low 15 
dose toxicity,from DNA reactive mutagenicity, based on chemical structure or other 16 
information. 17 
The possibility of refining the TOR approach by taking into account information 18 
on mode of action (MOA) for carcinogenicity was then investigated by Cheeseman et 19 
al. (1999), a possibility that had already been touched upon by Munro (1990). 20 
Cheeseman et al. (1999) analysed an expanded database of 709 carcinogens tested by 21 
the oral route. This analysis showed that Ames test negative carcinogens (193 out of 22 
709) were 8-fold less potent than Ames test positive carcinogens (249 out of 709), even 23 
if a linear non-threshold dose-response was assumed, regardless of MOA. Based on this 24 
analysis it was concluded that substances that were negative in the Ames test and for 25 
structural alerts for DNA-reactive genotoxicity (i.e. mutagenicity)might qualify for a 1 
higher dietary threshold, of around 0.25 µg/kg bw/day. Cheeseman et al. (1999) also 2 
identified structural classes associated with high potency for carcinogenicity, and on 3 
this basis recommended exclusion, i.e. N-nitroso-compounds, benzidine-structures and 4 
three other structural classes, from the TOR approach, even at the conservative value of 5 
0.025 µg/kg bw/day. 6 
Kroes et al. (2004) further analysed highly potent genotoxic carcinogens 7 
exceeding a 1 x 10-6excess risk below 0.0025 µg/kg bw/day exposure, using a slightly 8 
expanded set of 730 carcinogens. This enabled identification of structural classes which 9 
should be excluded from the application of the TTC approach and established that 10 
otherwise an exposure threshold of 0.0025 µg/kg bw/day was adequately protective 11 
even for those substances with structures raising alerts for DNA-reactive genotoxicity 12 
(i.e. mutagenicity). Kroes et al. (Kroes et al. 2004) classified carcinogens based on the 13 
structural alerts described by Ashby and Tennant (1991) and Cheeseman et al. ( 1999), 14 
and some of the latter structural groupings were modified. Those structural groups 15 
identified to comprise a significant number of carcinogens exceeding 1 x 10-6excess risk 16 
were aflatoxin-like compounds, N-nitroso-compounds and azoxy-compounds, as well as 17 
dioxins and steroids. The latter were however judged to represent non-genotoxic 18 
carcinogens with dose thresholds, so that only aflatoxin-like compounds, N-nitroso-19 
compounds and azoxy-compounds were proposed to be excluded from the TTC concept 20 
on the basis of their high potency as genotoxic carcinogens, the so-called cohort of 21 
concern (COC). 22 
EFSA (2012) discussed the fact that despite exclusion of the COC structural 23 
classes of Kroes et al. (2004), the carcinogen database of 730 substances still contained 24 
up to 30 substances exceeding the target excess risk of 1 x 10-6, representing about 4% 25 
of the database. However, this includes 2 dioxins and 5 steroids, inappropriately 1 
assessed by linear extrapolation, as they causecancer by non-genotoxic modes of action, 2 
for which there is evidence of biological thresholds, and the other substances represent 3 
only small fractions of their respective structural groups (3-14%). EFSA (2012) also 4 
noted that there is only a low probability (possibly as low as 10%) that any new 5 
substance would be carcinogenic and an even lower probability that this would be of 6 
high potency. It was further mentioned that EFSA typically assesses the level of 7 
concern from unavoidable exposure to genotoxic carcinogens using the margin of 8 
exposure (MOE), i.e. the ratio of the benchmark dose (BMD) lower confidence limit for 9 
a 10% response (BMDL10) for a tumour response in a bioassay to measured or 10 
estimated human exposure. Assuming linear low dose extrapolation, this MOE is 11 
‘equivalent’ to a 1x10-5excess risk and hence, a TTC of 0.0025 µg/kg bw per day would 12 
be more conservative than the accepted approach for substances specifically identified 13 
as genotoxic carcinogens. EFSA (2012) concluded that, after exclusion on the COC, for 14 
substances with structural alerts for DNA-reactive genotoxicity (i.e. mutagenicity), 15 
there is a very low probability (between 0-4%) of any appreciable cancer risk to humans 16 
from exposures below a TTC value of 0.0025 μg/kg bw per day. This value is 17 
equivalent to the TOR initially proposed by Rulis (1987). 18 
To date, although the anticipated difference in potency and dose response 19 
between genotoxic and non-genotoxic carcinogens has been discussed by most authors 20 
addressing the TOR and TTC concepts, this aspect has not been included in their 21 
analyses such that it would enable derivation of quantitative thresholds for separate 22 
distributions of the respective groups of carcinogens. 23 
Thresholds for impurities in pharmaceuticals 24 
While the necessity to assess the multitude of chemicals used in food contact 25 
applications or as food flavourings led to the development of the FDA TOR and the 1 
WHO/EFSA TTC concepts, respectively, it can equally be applied to other situations 2 
where there is a similar need. A pragmatic application of the TTC concept can be found 3 
in the control of mutagenic impurities in human pharmaceuticals. A recent harmonised 4 
guideline, ICH M7 (ICH 2014), provides a practical framework to limit potential 5 
carcinogenic risk from such impurities.  6 
The focus of the ICH M7 guideline is on DNA-reactive mutagenic substances. 7 
For those impurities which are, or are suspected of being, DNA-reactive mutagens, a 8 
TTC approach is used. This includes the results of structure-based approaches to predict 9 
the outcome of bacterial mutagenicity assays. Compounds in the highly potent structural 10 
classes comprising the cohort of concern are excluded from the TTC approach. 11 
Otherwise, for compounds with structural alerts for DNA-reactive mutagenicity, or with 12 
other evidence of DNA-reactive mutagenicity , exposure limits are based on the 13 
respective TTC values.  14 
The guideline notes that acceptable risk during the early drug development 15 
phase is set at a theoretically calculated level of approximately one additional cancer per 16 
million lifetime risk. However, risk is considered to be a function of both magnitude 17 
and duration of exposure and acceptable levels are adjusted accordingly, with shorter 18 
exposure durations during clinical trials allowing higher acceptable intake (i.e. TTC 19 
values adjusted upwards). For later stages in development and for marketed products, an 20 
increased cancer risk is considered acceptable due to the therapeutic benefits of the 21 
drug, and is set at a theoretically calculated level of approximately one additional cancer 22 
in one hundred thousand lifetime risk, corresponding to a TTC value of 1.5 µg/person 23 
per day (note that ICH explicitly expresses TTC values on a per person basis). This 24 
exemplifies that policy decisions on the risk acceptance levels can lead to different 25 
thresholds being applied. Regardless of such choices, a large, robust database, analysed 1 
in a consistent manner, should form the basis of threshold derivation. 2 
Underlying approach used to date to develop a TTC for substances that might 3 
be genotoxic carcinogens 4 
The TTC analyses to date have largely applied the methodology used by Gold et al. 5 
(Gold et al. 1989) for interpretation of cancer bioassay data. The TD50 was used to 6 
characterise cancer potency, and all substances were considered positive for 7 
carcinogenicity where at least one sex of one species showed a response with statistical 8 
significance of p ≤ 0.01. This approach is simple and pragmatic and allows derivation of 9 
conservative de minimis levels of exposure, but takes no account of a number of 10 
important aspects such as the shape of the dose-response curve and the human relevance 11 
or otherwise of rodent tumour findings. In many substance-specific risk assessments for 12 
carcinogenicity, increased understanding of modes of action and dose-response have led 13 
to criteria and methodologies different from those used to analyse the CPDB being 14 
developed and applied for the derivation of acceptable exposure levels. The question 15 
therefore arises of whether any of this knowledge or the approaches used can be applied 16 
to the derivation of TTC thresholds for such compounds.  17 
Factors potentially influencing the TTC values for DNA-reactive mutagenic 18 
and/or carcinogenic compounds 19 
Implicit assumptions in current approach 20 
The current, lowest TTC value of 0.0025 µg/kg bw per day was developed to protect 21 
against substances for which there is concern that they might be carcinogenic via a 22 
genotoxic MOA (i.e. DNA-reactive mutagenicity), assuming a linear, non-threshold 23 
dose-response relationship and an acceptable excess risk of 1 x 10-6. However, unlike 24 
other TTC values, this value was not obtained directly from distributional analysis, but 1 
included a number of other considerations (see previous sections). Amongst 2 
assumptions that have been made in the development of this TTC value are 1) the 3 
compounds in the CPDB are representative of the world of carcinogens, 2) there are 4 
sufficient compounds to obtain a reliable estimate of the distribution of their PODs, 3) 5 
carcinogens have a linear dose-response curve, 4) the carcinogenic response observed in 6 
laboratory animals is relevant to humans, 5) the acceptable excess risk for such 7 
compounds is 1 x 10-6. In the application of this TTC value it is assumed that 1) it is 8 
possible to identify reliably carcinogenic compounds acting via a genotoxic MOA (i.e. 9 
DNA-reactive mutagenicity, 2) those compounds that are not so identified are 10 
adequately covered by existing, higher TTC values (which would usually be 1.5 µg/kg 11 
bw per day, i.e. the TTC for Cramer class III compounds, or higher). 12 
Assumption that non-genotoxic carcinogens are covered by higher, existing 13 
TTC values 14 
Implicit in the current approaches to application of TTC values for genotoxic 15 
carcinogens is that if a compound is not predicted (or shown to be) a DNA-reactive 16 
mutagen, it will be adequately covered by higher TTC values, even if it is carcinogenic 17 
by some other MOA. In practice, this means that the acceptable exposure to such a 18 
compound would be up to 1.5 µg/kg bw per day, or higher depending on the Cramer 19 
class. There is certainly evidence that non-DNA reactive carcinogens are less potent that 20 
DNA-reactive carcinogens (Cheeseman et al. 1999). In addition, as such compounds are 21 
carcinogenic secondary to an adverse effect on the morphology or function of a target 22 
tissue (which is not necessarily the tissue in which carcinogenesis is observed), the 23 
application of default threshold-dependent considerations would apply. In practice, this 24 
means that if the human population is protected against the primary toxicity (which will 25 
occur at or below the critical POD on which the health-based guidance value is based 1 
(HBGV)), they should be protected against the carcinogenic effect. Typically, the 2 
HBGV would be obtained by applying an uncertainty factor of 100 to the POD for the 3 
critical effect, such as the BMDL10or NOAEL. 4 
The TTC value of 0.0025 µg/kg bw per day was developed to provide a nominal 5 
level of protection of 1 x 10-6overbackground. This was calculated assuming a linear, 6 
non-threshold dose-response. This is equivalent to dividing the BMDL10 by 105. Given 7 
that for a thresholded response the BMDL10would normally be divided by 102, the 8 
equivalent protection for non-DNA reactive carcinogens would be provided by a value 9 
of 2.5 µg/kg bw per day. Hence, the TTC value of 1.5 µg/kg bw per day for Cramer 10 
class III compounds (which is the likely default for most such compounds) would be 11 
adequately protective of such carcinogens, even if they were of similar potency to 12 
DNA-reactive genotoxic carcinogens. However, this analysis is predicated on the above 13 
assumptions, the implications of which would need to be determined before having 14 
confidence in this approach. 15 
Database used to establish the TTC of 0.15 µg/day is many years old and has 16 
not been updated for several years 17 
The database on which the TTC value for genotoxic (DNA-reactive mutagenic) 18 
carcinogens was based is several decades old, and whilst it has been updated since the 19 
original analysis, it has been ‘frozen’ for almost a decade. This is certainly a potential 20 
criticism. However, it should be noted that when the database was updated from 477 21 
carcinogens by approx. 50%, to 709 carcinogens, this did not significantly alter either 22 
the range of potencies or the peak position for the distribution (Cheeseman et al, 1999). 23 
In terms of assessing DNA-reactive mutagenic compounds, the static nature of the 24 
database may be of less concern than it first appears, for at least two key reasons. The 25 
chemicals first evaluated for carcinogenicity by the NCI and then the NTP were those 1 
that were of most concern in terms of exposure and potential potency (Munro 1990). As 2 
understanding of the structural characteristics leading to (DNA-reactive) mutagenicity 3 
increased, those companies developing novel chemicals in all sectors (e.g. 4 
agrochemicals, human medicines, food additives, industrial chemicals) introduced 5 
structural analysis and in vitro testing for mutagenicity at a very early stage of design 6 
and development. Hence, very few DNA-reactive genotoxic (DNA-reactive mutagenic) 7 
carcinogens are identified among new compounds requiring approval prior to use. In 8 
practice, this means that whilst it would be valuable to expand the CPDB, for the 9 
present exercise it is unlikely that very many suitable new compounds would be 10 
available. 11 
Advances in understanding both the implications of genotoxicity for 12 
carcinogenicity and in mechanisms of carcinogenesis 13 
Since the original publications on the TOR and TTC some two to three decades ago, 14 
there have been considerable advances not only in understanding modes of action for 15 
chemical carcinogenesis but also in the acceptability of such information in informing 16 
regulatory risk assessment. Hence, where a carcinogenic response has been shown to 17 
occur secondary to some other toxicological effect, it is accepted that this has a 18 
threshold and that often the application of conventional uncertainty factors to the critical 19 
effect in establishing HBGVs would be sufficiently protective against such a 20 
carcinogenic response. This also extends to consideration of the MOA for 21 
genotoxicity/mutagenicity. Where there is good toxicokinetic or, more often, 22 
toxicodynamic evidence for the existence of a threshold, conventional approaches to 23 
establishing HBGVs may be appropriately protective. Examples of the former are 24 
hydroquinone and phenol, which are rapidly detoxified in vivo. Examples of the latter 25 
are topoisomerase inhibitors, tubulin inhibitors, and inducers of reactive oxygen species 1 
(Parry et al. 1994; Committee on Mutagency of Chemicals in Food, Consumer Products 2 
and the Environment 2010). Indeed, recently evidence has emerged that even some 3 
DNA-reactive genotoxins such as ethyl methanesulfonate (EMS) have a clear threshold 4 
for mutagenicity (Doak et al. 2007; Gocke and Müller 2009).  5 
In 2007, it was discovered that a manufacturing batch of the drug Viracept 6 
(nelfinavir), an human immunodeficiency virus (HIV) protease inhibitor, was 7 
contaminated with EMS at levels that exceeded permissible levels by more than 1000-8 
fold (Muller and Singer, 2009). EMS is an established DNA-reactive mutagen, rodent 9 
carcinogen and teratogen (reviewed inGocke et al. 2009b). In the absence of human 10 
data, EMS exposure limits were based on the generic TTC-derived limit of 1.5 11 
µg/person per day as recommended in ICH M7 (discussed above). However, Doak et al. 12 
(2007) had provided reliable evidence for a threshold for chromosomal damage and 13 
gene mutations induced by EMS in vitro. Higher concentrations of EMS were clearly 14 
mutagenic, and other alkylating agents used (ethylnitrosourea (ENU) and 15 
methylnitrosourea (MNU)) exhibited apparently linear dose-effect relationshipsfor 16 
mutagenicity in these studies. The DNA alkylations induced by EMS, mainly at N7 and 17 
O6 positions of guanine, were considered to be repairable error-free by Base Excision 18 
Repair and Methyl Guanine Methyl Transferase. Additional testing in vitro and in vivo 19 
in a suitable range of assays confirmed that the mutagenicity of EMS exhibited a 20 
threshold (Gocke et al. 2009a). An EMS-specific permissible daily exposure of 100 21 
µg/day, based on the NOEL for induction of mutations in vivo and highly conservative 22 
safety factors (amounting to >10,000), for lifetime exposure to EMS was determined. 23 
This is clearly above the ICH TTC for DNA-reactive mutagenic carcinogens of 1.5 24 
µg/person per day (and the EFSA/WHO TTC value of 0.15 µg/person per day). Indeed, 25 
it is above the TTC for Cramer class III chemicals, of 60 µg/person per day.It should 1 
perhaps be noted that it is not yet clear how general is the acceptability of such evidence 2 
for thresholded mutagenicity and further work on this is ongoing. 3 
The CPDB of necessity comprises information obtained primarily on rodent 4 
cancer bioassays. Whilst, in general it is assumed, in the absence of evidence to the 5 
contrary, that the carcinogenicity of compounds acting by a DNA-reactive MOA will be 6 
relevant to humans, for those acting by other modes of action this is often not the case. 7 
A number of carcinogenic effects in rodents are now considered not to be relevant to 8 
humans, such as thyroid follicular cell tumours in rats resulting as a consequence of 9 
induced clearance of thyroid hormones by glucuronosyltransferase (UGT) (Cohen et al. 10 
2004), renal tumours in male rats resulting from binding to alpha2U-globulin (Meek et 11 
al. 2003), rodent liver tumours arising from activation of constitutive androstane 12 
receptor (CAR) or peroxisome proliferator-activated receptor (PPAR)-alpha(Klaunig et 13 
al. 2003; Corton et al. 2014; Elcombe et al. 2014). Those compounds that are 14 
carcinogenic by a MOA not relevant to humans should be excluded from the specific 15 
dataset used to determine an appropriate TTC value for genotoxic (i.e. DNA-reactive 16 
mutagenic) carcinogens, although in practice as the number of such compounds is 17 
small, this is unlikelyto impact on the distribution to any appreciable extent. 18 
Even for those compounds acting by a DNA-reactive mutagenic MOA, there are 19 
often quantitative differences, as the ultimate carcinogen is usually a reactive metabolite 20 
and the enzymes involved are frequently less active in humans than in rodents 21 
(DeKeyser et al. 2011). However, the same may be true for detoxifying reactions, so the 22 
net species difference would need to be determined on a case-by-case basis. 23 
Advances in dose-response modelling and recommendation for use of BMD 1 
approach 2 
The analyses on which the TTC value for genotoxic (DNA-reactive mutagenic) 3 
carcinogens is based used the TD50 as the POD for the carcinogenic response. The 4 
reliability of this as an estimate of carcinogenic potency has been questioned by a 5 
number of authors and organisations (e.g. EFSA 2009). As an alternative, the BMDL10 6 
is recommended (e.g. EFSA 2017). This takes better account of experimental variability 7 
in the bioassay and unnecessary extrapolation outside the experimental range of 8 
observation. The CPDB was updated to include estimates of the LTD10, the definition of 9 
which is analogous to that of the BMDL10. However, the estimates provided in the 10 
CPDB were derived mathematically from the existing TD50 values. The extent to which 11 
these vary from those obtained by de novo benchmark dose modelling is not known. It 12 
may be that they are acceptable surrogates, but this should be determined for an 13 
appropriate sub-set of compounds before accepting the values for further analyses. A 14 
judgement would then have to be made as to whether the improvement in accuracy 15 
would be justified by the effort necessary to achieve this. EFSA (2016) concluded that 16 
such effort would not be warranted in the case of non-cancer endpoints. 17 
Need to re-assess TTC values for genotoxic and carcinogenic compounds 18 
From the foregoing, it is apparent that the current TTC values for substances assumed to 19 
be DNA-reactive mutagens and carcinogens could be questioned, for a number of 20 
reasons. These values are likely to be conservative, as recognised by EFSA and WHO, 21 
who concluded that their re-assessment was not considered a priority (EFSA 2016). 22 
Nevertheless, the value of such a re-assessment was noted, in that it could enhance the 23 
power and range of chemical structures covered and that a number of the assumptions 24 
used in their derivation may be unnecessarily conservative (EFSA 2016). 25 
From a scientific perspective there is a clear case to be made for the re-1 
assessment of these values. Whilst existing values appear to be adequately protective of 2 
human health, a number of assumptions and approaches used in their original derivation 3 
have been superseded by advances in knowledge. Hence, to ensure a robust, transparent 4 
basis for all aspects of the TTC approach, re-assessment of these values is timely. In 5 
addition, restrictions on the use of chemicals should be commensurate with their risk, 6 
which may not be the case with the application of the current values. 7 
Outline of proposed re-evaluation of TTC values – proposed hierarchical 8 
analyses 9 
Genotoxic carcinogens 10 
Genotoxic chemicals are those that are capable of interacting with DNA (adduct 11 
formation, for example) directly or following formation of a DNA-reactive metabolite 12 
(Weisburger and Williams 1981) or of affecting the number or structure of 13 
chromosomes. Chemicals that are not capable of such effects are described as being 14 
non-genotoxic. However, the most potent genotoxic carcinogens are those that are 15 
DNA-reactive, leading to gene mutation. As these are the most readily identified by 16 
computational determination of structural alerts, and hence would be amenable to the 17 
application of the TTC approach, the emphasis in any re-evaluation should be on clearly 18 
identifying such compounds in the CPDB. There are a number of in vitro (e.g., Ames 19 
test, mammalian micronucleus assay, mammalian chromosome aberration assay, mouse 20 
lymphoma tk mutation assay and hprt mutation assay, described in OECD Test 21 
Guidelines 471, 487, 473, 490 and 476 respectively) and invivo (e.g., mammalian 22 
chromosome aberration, mammalian micronucleus, transgenic rodent (TGR) mutation, 23 
comet assay, and Pig-a mutation assay described in OECD Test Guidelines 475, 474, 24 
488, 498 and in Dertinger & Heflich, 2011 respectively) methods that can be employed 1 
to evaluate the genotoxic potential of a chemical. Most of these (e.g., micronucleus, tk, 2 
hprt, comet and Pig-a assays) provide an indirect measure of DNA damage, which is 3 
presumed, and interpreted as, being indicative of a capacity to cause mutations. When 4 
interpreting assays to evaluate genotoxicity, it is imperative that the impact of 5 
cytotoxicity, which can lead to false positive results, be considered, particularly for 6 
assays in vivo and with mammalian cellsin vitro. The objective of the evaluation of 7 
chemicals for their genotoxic potential is to gain knowledge regarding their potential 8 
ability to cause mutations invivo, under realistic conditions of exposure. Furthermore, 9 
invivo data are often more relevant for extrapolation to the consequences of human 10 
exposures than in vitro data.  11 
It has often been assumed that if a carcinogenic chemical is positive in a 12 
bacterial mutation (Ames) test then it can be classified as a genotoxic (DNA-reactive 13 
mutagenic) carcinogen. On a mechanistic basis, mutagenicity is not carcinogenicity, and 14 
the induction of a mutation is only one of a number of obligate steps in the progression 15 
of a normal cell and tissue to malignancy. Kirkland et al. (2006; 2014)have stated that 16 
20-30% of chemicals that are positive in the Ames test are not carcinogens. Bacteria and 17 
mammalian tissues have different structures, metabolism and defence mechanisms. ‘S9’ 18 
(postmitochondrial supernatant) from the liver of Aroclor 1254-treated rats,used as an 19 
exogenous metabolic system, might increase the likelihood of detecting mutagens 20 
requiringmetabolic activation, it is not very representative of the constitutive enzymes 21 
of xenobiotic metabolism present in mammalian cells. Hence, although a positive result 22 
in the Ames test is considered highly important in identifying a potential genotoxic 23 
(DNA-reactive mutagenic) carcinogen, a carcinogenic chemical that is also 24 
mutagenic/genotoxic in a number of different test systems, particularly in vivo, and 25 
across different endpoints (chromosome or DNA damage as well as gene mutation) is 1 
considered more likely to exert its carcinogenic activity via a mutagenicMOA. In vivo 2 
genotoxicity in the target species and target tissue for carcinogenicity provides 3 
considerable weight in determining whether a compound acts by a DNA-reactive 4 
mutagenic MOA. It is proposed that the most likely candidates to be considered 5 
genotoxic (DNA-reactive mutagenic) carcinogens, and therefore priority chemicals for 6 
determining TTCs, are those described in Table 1. The strength of the genotoxicity 7 
profile is highest in Group 1, where positive results are obtained for more than one 8 
endpoint (gene mutation, chromosomal or DNA damage) both in vitro and in vivo. 9 
Chemicals with the weakest profile show positive results in only a single test in addition 10 
to being positive in the Ames test. If chemicals show mixed positive and negative 11 
results, or only in vitro results are available, they may still be genotoxic carcinogens but 12 
the evidence linking the positive genotoxicity results to tumour induction is less strong. 13 
Given that the in vivo liver unscheduled DNA synthesis (UDS) test has been shown to 14 
be insensitive to a number of carcinogens suspected of operating via a DNA-reactive 15 
mutagenic MOA (see Kirkland and Speit, 2008), if a carcinogen is negative in the UDS 16 
test but gives positive results in other in vivo tests it could be included for 17 
consideration. Thus, positive results in the UDS assay are considered a relevant 18 
indicator of carcinogenic potential. However,since the comet assay is considered an 19 
‘indicator test’, in that DNA strand breaks may be effectively repaired or lead to 20 
lethality, positive results only in the comet assay may not be indicative of the ability to 21 
induce permanent DNA changes. Therefore, for any carcinogens that are positive in the 22 
Ames test, but for which the only in vivo result is a positive comet assay, the 23 
appropriateness of considering such a compound as a DNA-reactive mutagenic 24 
carcinogen is uncertain and if possible additional information should be sought. 25 
It is hoped that a sufficient number of carcinogens with a strong 1 
genotoxicity/mutagenicity profile could be identified by such an analysis to allow an 2 
adequate re-assessment of the TTC values. However, if too few carcinogens are found 3 
using this approach, the next step would be to add carcinogens for which there are 4 
mixed (both positive and negative) in vivo genotoxicity results. A careful evaluation of 5 
the robustness of the respective positive and negative results would be needed, such that 6 
a conclusion of most likely genotoxic MOA could be made. Given the propensity of 7 
mammalian cell genotoxicity tests to give ‘misleading’ positive results (Kirkland et al. 8 
2006; Kirkland et al. 2007) particularly from older published studies where extreme 9 
conditions may not have been controlled, or where p53-deficient rodent cell lines of 10 
unauthenticated origin were used, it is recommended that a conclusion of genotoxic 11 
MOA should not rely solely on in vitro results. 12 
Non-genotoxic carcinogens 13 
Traditionally, it has been assumed that a TTC value set for genotoxic (DNA-reactive 14 
mutagenic) carcinogens would be sufficiently protective for non-genotoxic carcinogens 15 
i.e. thresholds for non-genotoxic carcinogens would be expected to be higher than those 16 
for DNA-reactive mutagenic carcinogens and would be covered by existing, higher 17 
TTC values. However, this has never been independently tested (but see Cheeseman et 18 
al. (1999), discussed above). In order to do that, a priority list of non-genotoxic 19 
carcinogens relevant and potentially relevant to humans should be identified. 20 
It is theoretically more demanding to identify a non-genotoxic MOA for a 21 
carcinogen than a genotoxic MOA. Since mutagenic, clastogenic and/or aneugenic 22 
activities may be involved in one or more key steps of the carcinogenic process, 23 
negative results would need to be obtained across all of these endpoints in order to 24 
conclude absence of genotoxic activity unequivocally. The tests in which such negative 25 
results were obtained would also need to be rigorous, for example, the following when 1 
conducted according to the Organisation for Economic Co-operation and Development 2 
(OECD) or equivalentguidelines (see also Eastmond et al. 2009): 3 
• Bacterial mutation tests including S. typhimurium or one of the E. Coli WP2 4 
strains 5 
• Chromosomal aberration or micronucleus tests performed to acceptable levels of 6 
cytotoxicity, scoring sufficient cells, and including short and prolonged 7 
treatment times 8 
• Mammalian cell gene mutation tests, in which sufficient cells have been treated, 9 
subcultured and plated for mutant selection. 10 
In addition, absence of structural alerts, and absence of adduct formation with 11 
DNA would add weight to a conclusion of absence of genotoxic activity. At this time 12 
we are not aware of any curated databases of clearly non-genotoxic chemicals, and 13 
therefore identifying a priority list of human-relevant (and potentially relevant) non-14 
genotoxic carcinogens for re-assessment of TTC values will probably need to be carried 15 
out on a case-by-case basis. Despite the challenges in forming a priority list of human-16 
relevant (and potentially relevant) non-genotoxic carcinogens, there are several well 17 
documented processes that can lead to tumour formation via a non-genotoxic MOA (see 18 
Hernandez et al. 2009; BAuA, 2014; Luijten et al. 2016; Jacobs et al. 2016), for 19 
example: 20 
• (Peroxisome proliferation) 21 
• (CAR/PXR activation) 22 
• AhR activation 23 
• Cytotoxicity 24 
• Growth stimulation (mitogenesis) 1 
• Inflammation 2 
• Immunosuppression 3 
• Endocrine modification. 4 
The first two modes of action are considered of doubtful, if any, significance to 5 
humans (Corton et al. 2014; Elcombe et al. 2014). Substances acting via these agreed 6 
modes of action, but excluding any possible DNA-reactivity/genotoxicity, could be used 7 
to identify a priority list of human-relevant (and potentially relevant) non-genotoxic 8 
carcinogens. 9 
Proposed approach to re-assess TTCs for carcinogens 10 
Revise and expand CPDB 11 
Inclusion/exclusion criteria 12 
The current TTC value of 0.0025 µg/kg bodyweight per day for genotoxic (DNA-13 
reactive mutagenic) carcinogens was based on analyses of information from the CPDB. 14 
Re-evaluation of this database to determine TTC values for DNA-reactive mutagenic 15 
and non-genotoxic carcinogens relevant and potentially relevant to humans could be 16 
achieved using the hierarchical approach outlined above. A set of criteria are proposed 17 
for selecting suitable data to ensure the dataset underlying these TTC values is 18 
scientifically robust and transparent. These criteria include general study design 19 
parameters as well as more specific inclusion and exclusion criteria. Since this exercise 20 
will be resource intensive, it is proposed that it would be more efficient to collect all 21 
potentially useful studies in a new database. From this database, the data qualifying for 22 
determining the TTC values can be selected. These data are further referred to as the 23 
‘dataset’. A database constructed in this way would be suitable for a number of 1 
applications, additional to the selection of a subset of data for re-assessment of the TTC 2 
values. 3 
General criteria for the CPDB 4 
In total, five general criteria for the database were defined and evaluated. These are as 5 
follows: 6 
Box 1: General criteria 7 
 8 
(1) Study type: carcinogenicity studies. Preferably, the cancer potency database should 9 
contain studies performed according to, or consistent with, OECD Test Guideline 451 10 
on Carcinogenicity Studies (OECD 2009a) or Test Guideline 453 on Combined Chronic 11 
Toxicity/Carcinogenicity Studies (OECD 2009b). In any case, only studies examining 12 
tumour responses will be relevant for the database. 13 
(2) Relevance and reliability: studies with Klimisch score 1, 2 or 4. The reliability 14 
categories as described by Klimisch et al. (1997) have proven to be useful in regulatory 15 
risk assessment, for example in the OECD High Production Volume (HPV) program 16 
and under REACH. They take into account the reliability, relevance and adequacy of 17 
(1) Study type: carcinogenicity studies; 
(2) Relevance and reliability: studies with Klimisch score 1, 2 or 4; 
(3) Route of exposure: studies that used either oral dosage regimen or 
inhalation; 
(4) Species: include any; 
(5) Studies listed in CPDB as ‘TBA’, ‘MXA’, or ‘MXB’: exclude. 
data for use in reaching hazard/dose-response conclusions on an endpoint for a specific 1 
substance. In addition, consideration is given as to whether the administered material 2 
has been appropriately characterized and that information on this has 3 
beenprovided.Studies with a Klimisch score of 1 areperformed according to generally 4 
valid and/or internationally accepted testing guidelines or in which the test parameters 5 
documented are based on a specific (national) testing guideline (preferably performed 6 
according to good laboratory practice (GLP)) or in which all parameters described are 7 
closely related/comparable to a guideline method. Studies with a Klimisch score of 2 8 
are those in which the test parameters documented do not totally comply with the 9 
specific testing guideline, but are sufficient to accept the data or in which investigations 10 
are described which cannot be subsumed under a testing guideline, but which are 11 
nevertheless well documented and scientifically acceptable. Studies with a Klimisch 12 
score of 3 are those in which there are interferences between the measuring system and 13 
the test substance or in which organisms/test systems were used which are not relevant 14 
in relation to the exposure (e.g., unphysiologic pathways of application) or which were 15 
carried out or generated according to a method which is not acceptable, the 16 
documentation of which is not sufficient for an assessment and which is not convincing 17 
for an expert judgment, Studies with a Klimisch score of 4 are those which do not give 18 
sufficient experimental details and which are only listed in short abstracts or secondary 19 
literature (books, reviews, etc.).It is proposed that studies with a Klimisch score of 1 20 
(acceptable without restrictions), 2 (acceptable with restrictions) or 4 (not assignable) 21 
should be considered for inclusion, in terms of ‘potentially useful’, in the database. 22 
Inclusion of studies with a Klimisch score of 4 in the dataset used to re-evaluate the 23 
TTC values would have to be decided on a case-by-case basis. Discriminating between 24 
studies with a Klimisch score of 1 versus a score of 2 may be difficult due to a lack of 25 
information provided on guideline compliance. This, however, should not pose a 1 
problem when re-evaluating data. Studies with a Klimisch score of 3 are not considered 2 
suitable for inclusion in the database. The Klimisch score should be noted in the 3 
database. 4 
(3) Route of exposure: studies that used either oral dosage regimen or inhalation.For 5 
the database, data for chemicals studied using oral (diet, gavage, drinking water) or 6 
inhalation as the route of exposure should be collected, as they are physiologically 7 
relevant exposure routes in the safety assessments of chemicals. For volatile chemicals, 8 
in particular, a significant number of systemic carcinogens might be missed if inhalation 9 
studies are excluded. Information on the extent of systemic exposure should be 10 
recorded, when available and the absence of such information noted. Inclusion of data 11 
from studies using inhalation exposure should be included in the TTC dataset only when 12 
relevance to oral exposure is plausible and when it is possible to calculate the equivalent 13 
oral exposure. When calculating the POD for the TTC dataset, such exposures should be 14 
recalculated to give mg/kg bw per day. Studies using dermal application or 15 
intraperitoneal, intravenous or subcutaneous injection as the route of exposure are 16 
generally not considered suitable for derivation of potency values that would be 17 
physiologically relevant for normal routes of exposure and should therefore be omitted.  18 
(4) Include any species.Studies in any species are considered potentially relevant and 19 
should be included in the database. Whether or not a given study should be included 20 
into the TTC dataset will depend on various factors, such as, for example, availability of 21 
historical control data and animal numbers used. It is noted that most studies with 22 
unusual species will probably not meet the quality criteria. 23 
(5) Studies listed as ‘TBA’, ‘MXA’, or ‘MXB’ in CPDB: exclude.The CPDB reports 1 
TD50 values that have been derived from either statistically significant findings in a 2 
single tissue, which should be included in the dataset for relevant studies, or from 3 
findings observed in all tumour bearing animals (TBA), from more than one site, 4 
combined by NCI/NTP (MXA), or from more than one site, combined by Berkeley 5 
(MXB). Data from studies listed in the CPDB as ‘TBA’, ‘MXA’, or ‘MXB’ should be 6 
excluded from the dataset, as the biological relevance of such grouping, comprising a 7 
range of pathologies and potential modes of action, is difficult to interpret. The FDA 8 
CFSAN 2012 study (J. Aungst, K. Arvidson, D. Rua, D. Hristozov, B. Mugabe and A. 9 
McCarthy, C. Yang, M. A. Cheeseman. CFSAN/OFAS 2012) also excluded these 10 
mixed combined tumours. 11 
Criteria for inclusion in the cancer potency dataset 12 
In addition to these general criteria, specific inclusion criteria for acceptable positive 13 
studies and acceptable negative studies are proposed. Negative studies will be useful to 14 
be able to conduct a Weight of Evidence (WOE) analysis for substances with mixed 15 
results, i.e., with different results from multiple studies (see below). The inclusion 16 
criteria listed below should be applied as guidelines with some flexibility to ensure that 17 
no studies relevant for potency setting are lost. In general, all criteria should be met. 18 
Box 2: Inclusion criteria 19 
 1 
Acceptable positive studies 2 
Studies in which the substance is considered positive or negative for carcinogenicity by 3 
an authoritative body, such as the NTP, should be so noted in the database. However, it 4 
is recommended that the findings should also be evaluated independently, using the 5 
criteria discussed below, and a conclusion on the acceptability of positive or negative 6 
findings based on this assessment should also be noted. 7 
Acceptable positive studies 
(1)  Tumour findings relevant or assumed to be relevant to humans; 
(2)  Tumour incidences based on one species and one sex per one tissue/organ;  
(3)  Studies with exposures shorter than usual (≤ 18 months for mice and ≤ 24 months 
for rats) included if statistically significant (for example, one-tailed test for pair-wise 
comparisonfor a common tumour type, P≤0.01); 
(4)  Sufficient number of animals per sex and dose group evaluated for carcinogenicity 
by the end of the study to enable a reliable estimate of the POD.Acceptable negative 
studies 
(1)  Exposure duration ≥ 18 months for mice and ≥ 24 months for rats; 
(2)  MTD achieved,limit dose reached for practical reasons, or acceptable multiple of 
human exposure (internal dose) achieved;  
(3) Group size minimum (per sex) is 40, with survival being at least 50% at end of 
study; 
(4)  Notumour shows an incidence statistically significantly different from that in the 
concurrent control group. 
 
 
(1) Tumour findings relevant to humans. Unless there is strong and accepted (by 1 
authoritative bodies) evidence to the contrary, a carcinogenic response induced in 2 
experimental animals by a DNA-reactive mutagenic MOA (likely or possible) will be 3 
considered relevant to humans. This applies even to tissues where there is no human 4 
counterpart, such as the Harderian gland. 5 
There are a few site-of-contact carcinogens which exhibit some genotoxicity in 6 
vitro but where the evidence for their carcinogenicity is for a MOA that does not 7 
involve DNA reactivity. An example would be ethyl acrylate in the rat and mouse 8 
forestomach, where the concentration is uniquely high due to the particular anatomy and 9 
physiology of this rodent-specific organ and the MOA appears to involve local irritation 10 
(Proctor et al. 2007). Where there is general acceptance by the scientific community 11 
(and by one or more authoritative bodies) that such a response is not relevant to humans 12 
because there is no human counterpart to the forestomach, a similar position should be 13 
adopted.  14 
Where a carcinogenic response is through a non-genotoxic MOA, human 15 
relevance assessed using the WHO IPCS Human Relevance Framework (Boobis et al. 16 
2006; Boobis et al. 2008; Meek et al. 2014) should be determined. Where there is 17 
general acceptance by the scientific community (and by one or more authoritative 18 
bodies) that a carcinogenic response in experimental animals is not relevant to humans 19 
this will be deemed sufficient evidence to exclude these data from TTC analysis. In the 20 
case of non-genotoxic carcinogens, site of effect is an important factor in determining 21 
human relevance. Where such a non-genotoxic response is observed only in a tissue 22 
with no human counterpart, this will be strong evidence for exclusion of the data from 23 
TTC analysis (see Edler et al. 2014).  24 
(2) Tumour incidences based on one species and one sex. Tumour incidences and PODs 1 
in the database should be based only on specific site/sex, species and tissue/organ. 2 
Expert judgement and transparent weight-of-evidence assessment will be needed to 3 
determine if isolated increases in one sex of one species in one tissue or whether 4 
conflicting results in different studies in the same tissue, sex, strain and species are 5 
sufficient evidence of a relevant response for inclusion in the dataset. Data where 6 
tumour findings from both males and females or different sites have been added 7 
together would be deemed not informative. There is no firm recommendation in terms 8 
of statistical test to be performed, maximal P-value, or minimal sample size for 9 
inclusion into the database. However, only substances with a relevant positive (i.e. 10 
statistically significant) tumour response should be included into the TTC dataset.  11 
(3) Studies with exposures shorter than usual (≤ 18 months for mice and ≤ 24 months 12 
for rats) included if statistically significant (e.g. one-tailed test for a common tumour 13 
type, P≤0.01). Potent carcinogens and/or high doses may cause tumour incidences to 14 
increase early, relative to controls, so that studies of shorter duration than normal may 15 
still be sufficient to enable characterisation of the dose-response relationship. Hence, 16 
these studies may still be useful and should therefore be included into the database. 17 
Responses in this type of study would have to be extrapolated for lifetime exposure 18 
when estimating potency. Inclusion into the TTC dataset should be decided on a case-19 
by-case basis (expert judgement). 20 
(4) Sufficient number (usually at least 10) of animals per sex and dose group evaluated 21 
for carcinogenicity by the end of the studyto enable a reliable estimate of the POD. If a 22 
positive study has only a few animals per group, the uncertainty in the TD50 estimate 23 
becomes very large. Applying a BMD approach, i.e. using a BMDL10 instead of a TD50 24 
as POD, will not overcome this issue because the number of dose groups in a 1 
carcinogenicity study is usually fairly low (see Slob, 2014). A judgement would have to 2 
be made on the acceptability of the POD estimate, based on the difference between the 3 
BMD, BMDL and BMDU (estimates of the 95% lower and upper confidence limit on 4 
the BMD, respectively) (e.g. EFSA 2009). 5 
Acceptable negative studies 6 
(1) Exposure duration ≥ 18 months for mice and ≥ 24 months for rats. This criterion is 7 
proposed because in cases where studies are negative, it study duration is short it cannot 8 
be excluded that this was the primary reason for the absence of an observable increase 9 
in tumour incidence. For other species (hamster, monkeys, dogs, etc), ideally life-time 10 
exposure should be considered; however, for species other than rat or mouse, adequacy 11 
of study duration should be by expert judgement on a case-by-case basis. 12 
(2) MTD achieved,limit dose reached for practical reasons, or acceptable multiple of 13 
human exposure (internal dose) achieved. In a carcinogenicity study, it is usually 14 
required that the highest dose achieved is the MTD to ensure the adequacy of neoplastic 15 
hazard identification. In combination with lower doses the use of the MTD also enables 16 
a dose response evaluation. It is noted that for pharmaceuticals and to some extent also 17 
agrochemicals, the top dose can be set on considerations of human exposure and/or 18 
saturation of exposure. Classical considerations to define whether an MTD or adequate 19 
dosage has been achieved include the following (see also Rhomberg et al. 2007). 20 
The highest dose level elicited evidence of toxicity (2.1, 2.2, or 2.3 below), is a 21 
limit dose (2.4), or is an acceptable multiple of human exposure (particularly for human 22 
pharmaceuticals (2.6): 23 
(2.1) Depression of body weight gain (approximately 10%) or any other adverse 1 
effect that may limit the high dose level that could be humanely achieved 2 
(OECD 2009a) 3 
(2.2) Data from dose-setting studies that indicate the dose level is approaching a 4 
toxic level, even if not observed in the carcinogenicity study itself. For 5 
example, an incrementally higher dosage in the dose setting study was 6 
overtly toxic; 7 
(2.3) Although an MTD in terms of body weight gain was not achieved, overt 8 
organ toxicity was observed; 9 
(2.4) Alternatively, the high dose may be defined as a maximum practical 10 
dosage, on the nutritional basis that the concentration of the chemical 11 
should not normally exceed 5% of the total diet (OECD 2009a) or is a 12 
limit dose (e.g. 1000 mg/kg/body weight in OECD 408 or dose setting 13 
studies); 14 
(2.5) There is robust evidence that systemic exposure does not increase beyond 15 
the top dose used, even if below a limit dose, due to saturable absorption. 16 
(2.6) The high dose results in a systemic exposure that is a large multiple of the 17 
human area under the exposure curve (AUC), typically 25-fold or greater, 18 
for substances that have similar metabolic profiles in humans and rodents 19 
and low organ toxicity in rodents (i.e., high doses are well tolerated in 20 
rodents). This approach is most often used for human pharmaceuticals, for 21 
which suitable pharmacokinetic data should be available. 22 
Fulfilment of classic MTD acceptance criterion may be of limited importance 23 
for substances of high neoplasticpotency. Use of sufficiently high dosage is likely to be 24 
a more important criterion for inclusion of substances of low potency, for which no 1 
tumours were observed.  2 
The main need is to be able to define a POD for any neoplastic change in a 3 
study. It is quite possible that an individual carcinogenicity study fails to reach a MTD 4 
for non-neoplastic change but is highly relevant due to high neoplastic potency. 5 
Conversely, it is quite possible that an individual carcinogenicity study fails to reach a 6 
MTD for non-neoplastic change or neoplastic change, and fails to show hazard 7 
potential, but nevertheless is sufficient to indicate that the substance has little or no 8 
carcinogenic potency and thus a high POD (if at all). 9 
It is also possible that a study is considered of uncertain relevance for POD 10 
determination if excessive toxicity occurred at all dosages, and a carcinogenic response 11 
seen in the study is considered likely secondary to the toxicity observed. This would 12 
need to be judged on a case-by-case basis. 13 
In summary, whether MTD was achieved or not is of limited relevance to the 14 
use of study data in the database and dataset, and generally would not be a basis to 15 
consider a study as scientifically inadequate for use in defining carcinogenic 16 
threshold(s), if potency information is available. Therefore the MTD requirement 17 
should in general be considered using expert judgement on a case-by-case basis. 18 
(3) Group size minimum (per sex) is 40, with survival being at least 50% at end of 19 
study. In any cancer bioassay, as indeed in any quantitative scientific study, it is not 20 
possible to prove a negative. Statistical analyses are undertaken to determine whether 21 
the null hypothesis can be rejected, in this case that substance administration has no 22 
effect on tumour incidence. Lack of statistical significance does not prove no effect, 23 
only that there is no evidence for an effect within the power of the study. Hence, to 24 
ensure adequate power in studies with negative findings, and provide reasonable 25 
confidence in the upper limit of any possible response in the absence of statistical 1 
significance, the minimum group size per dose per sex should be 40 animals (for larger 2 
species, such as dogs and monkeys expert judgement will be needed to assess 3 
acceptable group size). In addition, because of the latency of some tumour types, at least 4 
50% of the animals should be evaluable histologically at study termination, to ensure 5 
that there is sufficient power for assessment at the end of the study. Whilst large group 6 
sizes could result in survival of at least 20 animals at the end of the study, even with 7 
extensive precedent mortality, this may obscure a particularlyaggressivecarcinogenic 8 
response and hence would not be acceptable for the purposes of the present exercise. 9 
(4) No tumour shows an incidence statistically significantlydifferent from that in the 10 
concurrent control group. In studies that meet all of the inclusion criteria, including 11 
adequacy of dosing regimen, dose group size and study duration, where there is no 12 
statistically significant increase in tumour incidence in any tissue (e.g. one-tailed test, 13 
P≤0.01 for pairwise comparison of a common tumour type), they should be considered 14 
negative for carcinogenicity.  15 
Consistent with the inclusion criteria for acceptable positive and acceptable 16 
negative studies a total of four exclusion criteria were proposed. 17 
Box 3: Exclusion criteria 18 
 19 
Unacceptable positive studies 
(1)  Tumour responses observed only at doses that exceed the MTD; 
(2)  Studies performed in short-term animal models of carcinogenicity and other study 
types; 
(3)  Single dose group studies; 
(4)  Tumour findings irrelevant for humans. 
Unacceptable positive studies 1 
(1) Tumour responses observed only at doses that exceed the MTD. The MTD may be 2 
deemed to be exceeded based on:  3 
(1.1) Excessive depression of body weight gain;  4 
(1.2) Excessive mortality (from non-cancer causes);  5 
(1.3) Signs of excessive toxicity such as marked non-neoplastic 6 
histopathological changes, clinical signs, haematology – even if there is 7 
not an excessive depression of body weight gain.  8 
It is recommended that the option to evaluate any bioassay that reports a positive 9 
tumour response, on a case-by-case basis, with regard to whether or not the MTD has 10 
been exceeded be kept open. Also, it should be borne in mind that target organ toxicity 11 
may be the precursory basis for tumour development. 12 
(2) Studies performed in short-term animal models of carcinogenicity and other study 13 
types. Models such as transgenic mice and partially hepatectomised rats might be of 14 
value in assessing carcinogenic hazard but they are not helpful in assessing potency 15 
towards normal organisms. Hence, it is recommended that data obtained from such 16 
models should not be used for re-evaluating the TTC values. Similarly, any other study 17 
type for which there is insufficient experience on potency correlation to normal 18 
exposure situations or organisms, e.g. genetically highly susceptible mouse strains or 19 
newborn mice, should be considered irrelevant for this purpose.  20 
(3) Single dose group studies. Data from single dose studies should be collected for the 21 
database, because they are potentially useful in a WOE approach. However, single dose 22 
studies do not permit meaningful determination of potency and hence should not be 1 
included in the TTC dataset. 2 
(4) Tumour findings irrelevant for humans.See inclusion criteria.  3 
Assessment of dataset entries 4 
Application of the hierarchical analysis outlined in section on “Outline of proposed re-5 
evaluation of TTC values – proposed hierarchical analyses”, combined with the criteria 6 
listed above, would hopefully result in a dataset comprising a sufficient number of 7 
carcinogens that are considered most likely to have a genotoxic MOA. In addition, a 8 
dataset of non-genotoxic carcinogens relevant or potentially relevant to humans should 9 
be identified. 10 
Evidence of a causal role of genotoxicity in the carcinogenic MOA 11 
Each carcinogenic response included in the database should be assessed using rigorous 12 
and transparent weight-of-evidence for the contribution of genotoxicity to the MOA for 13 
the carcinogenic response observed. It is proposed that the IPCS MOA Human 14 
Relevance framework be used for this purpose (Boobis et al. 2006; Boobis et al, 2008; 15 
Meek et al. 2014). Preston & Williams (2005) provide a specific example of application 16 
of the framework in this way. Multiple sources of information, including data on 17 
genotoxicity, precursor effects, mechanistic studies and structural analogues will be of 18 
value in such assessment. It is suggested that, ideally, compounds should be identified 19 
as DNA-reactive mutagenic carcinogens (clear threshold, no clear evidence of a 20 
threshold for carcinogenicity), carcinogens involving a different genotoxic MOA (i.e. 21 
not via DNA-reactive mutagenicity),non-genotoxic carcinogens (relevant or potentially 22 
relevant to humans), genotoxic and carcinogenic but insufficient evidence to determine 23 
causality (clear threshold, no clear evidence of a threshold for carcinogenicity). Such 1 
identification will enable sensitivity analyses to be performed when deriving TTC 2 
values. 3 
POD 4 
Ideally, the same method would be used to determine the POD for all substances in the 5 
TTC dataset. As indicated above, there is a clear preference that this should be the 6 
BMDL10, based on the results on animal bioassays (see section on “Advances in dose-7 
response modelling and recommendation for use of BMD approach”). This would likely 8 
require benchmark dose modelling of a large number of datasets. As discussed in 9 
section on “Need to re-assess TTC values for genotoxic and carcinogenic compounds”, 10 
it is unknown whether the estimates of the LTD10, currently available in the CPDB, are 11 
sufficiently reliable and similar to BMDL10 values calculated by de novo benchmark 12 
dose modelling. This should be evaluated for appropriate subsets of chemicals, both for 13 
DNA-reactive mutagenic and human-relevant (and potentially relevant) non-genotoxic 14 
carcinogens, before using LTD10 values for further analyses. Given the number of 15 
decisions that have to be made when deriving BMDs and BMDLs, it will be essential 16 
that a consistent, transparent approach be used for any such modelling (e.g. EFSA 17 
2009). 18 
There may be multiple BMDLs for a given tumour response, either in the same 19 
study because more than one model is acceptable, or in more than one study of 20 
comparable design. Consideration will need to be given as to which BMDL value 21 
should be used in the analysis (lowest, mean, model average, etc). Guidance on this can 22 
be found in EFSA (2017). 23 
Where administration of the test article was less than daily (for oral exposures) 24 
or not for 24 h per day (for inhalation), appropriate adjustment of the POD will be 25 
necessary (seeEnvironmental Protection Agency (EPA), 2005).In situations where 1 
duration of exposure was for less than lifetime, see above for inclusionand exclusion 2 
criteria.Where necessary, appropriate defaults may have to be used for physiological 3 
variables, such as breathing rate, food consumption and water consumption, such as in 4 
the EPA (2011) Exposure Factors Handbook. 5 
Extrapolation to human equivalent dose 6 
In all previous analyses to derive TTC values for genotoxic (DNA-reactive mutagenic) 7 
carcinogens, linear extrapolation from the PODs in animal cancer bioassays to a 8 
nominal minimal human risk value has been used to determine VSDs for distributional 9 
assessment. The minimal excess human risk value used has been 1 x 10-6, other than for 10 
impurities in human pharmaceuticals in late stage development or clinical use, when a 11 
value of 1 x 10-5 has been used (see sections on “FDA TOR and additional thresholds 12 
developed from it” and on “Database used to establish the TTC of 0.15 µg/day is many 13 
years old and has not been updated for several years”). In the first analyses to reassess 14 
the TTC values for genotoxic carcinogens, it is suggested that VSDs based on a minimal 15 
excess human risk value of 1 x 10-6 be used, to enable comparison with previous TTC 16 
values. Additional analyses could then be performed using different approaches, as 17 
appropriate, for example different minimal human risk values, relaxation of the 18 
assumption of linear, no threshold depending on MOA, WOE for genotoxicity, and 19 
nature of genotoxicity. 20 
Importance of rigorous quality control of data and open access 21 
It is strongly recommended that all data be subjected to rigorous quality assurance and 22 
quality control, in order to prevent data entry errors and create a reliable, sound and 23 
trustworthy database. This database and all associated information should be freely 24 
available to the public. Permitting open access to the database will allow other 1 
researchers to conduct similar or related analyses; moreover, it will enhance adoption 2 
and implementation of any new TTC values for risk assessment purposes. 3 
Identification of 'relevant' genotoxins using structural alerts 4 
The cancer TTC value is applicable only to those compounds that are likely to be 5 
carcinogenic by a DNA-reactive mutagenic MOA. Hence, in applying the TTC 6 
approach it is necessary to identify those compounds that are likely to be DNA-reactive 7 
mutagens. Genotoxicity comprises a number of different modes of action, amongst 8 
which direct interaction with DNA of the compound itself or a metabolite leading to 9 
covalent modification of DNA is of most concern. Indeed, there is good evidence that 10 
other genotoxic modes of action either do not lead to carcinogenesis or exhibit a clear 11 
threshold, and would be covered by higher TTC values. Indeed, this is the basis for the 12 
various current TTC decision trees; it is necessary only to identify putative DNA-13 
reactive mutagens for application of the lowest TTC value of 0.0025 µg/kg bw per day 14 
and compounds that do not fall into this category will be covered by other, higher TTC 15 
values. It is thus critical in the application of the TTC approach that those compounds 16 
likely to be mutagenic via a DNA-reactive mode action can be reliably identified on the 17 
basis of structure alone.  18 
EFSA and other work on identification of DNA-reactive mutagenic compounds 19 
using structural alerts 20 
EFSA, through their Panel on Plant Protection Products and their Residues (PPR Panel), 21 
reported the findings of an EFSA-commissioned study undertaken by the European 22 
Commission’s Joint Research Centre (JRC) to evaluate the toxicological relevance of 23 
metabolites of pesticide active substances (EFSA 2012). The JRC report (2010) 24 
conceived a conceptual framework, based on the OECD Principles for the Validation of 1 
QSARs (quantitative structure–activity relationships), to review (Q)SAR approaches – 2 
for the purposes of this manuscript the term (Q)SAR is inclusive of both structural alert 3 
and related SAR approaches as well as statistical models such as QSARs; where 4 
necessary in this manuscript SARs are considered separately from QSARs. In addition, 5 
for DNA-reactive mutagenicity, a number of expert systems, representing a knowledge-6 
driven rulebase of structural alerts (DEREK), statistical models (CAESAR, LAZAR, 7 
TOPKAT, HazardExpert and ToxBoxes) and a hybrid rule-based / statistical system 8 
(Toxtree) were evaluated with regard to predictions of the results of over 1,500 9 
substances. The chemical space of the substances, as compared to e.g. pesticides, was 10 
evaluated, providing some – if not complete - insight into the relative applicability 11 
domains.  12 
The overall consensus from JRC and the EFSA panel is that there is utility in 13 
predicting DNA-reactive mutagenicity from (Q)SAR models. Improvements in 14 
accuracy of prediction are seen when forming some type of consensus between a rule–15 
based and a statistical system. Overall the conclusions appear sound – (Q)SAR methods 16 
may be used with some confidence, within defined areas of chemical space. This may 17 
be assisted by the use of read-across (assuming sufficient data are available).  18 
Advances in software for identifying structural alerts 19 
Structural alerts are fragments of molecular structures or functional groups that convey 20 
some type of biological activity. They vary widely in their form, use and application. In 21 
the context of this application they will assist in the identification of DNA-reactive 22 
mutagens(and hence putative carcinogens) since they are ideally suited for identifying 23 
fragments of molecules associated with mutagenicity. They are based on a rich and long 24 
history of toxicological understanding, with the original fragments predating 25 
computational technologies to make them useable e.g. the bay region of polycyclic 1 
aromatic hydrocarbons(PAHs), which is the area bounded by three contiguous adjacent 2 
bonds, one from each of three fused aromatic rings of a PAH molecule (Lehr et al. 3 
1985). The use of structural alerts crystallised with the seminal publication of Ashby 4 
and Tennant (1988) that compiled, in parchmento(in their paper), over 20 fragments 5 
associated with electrophilic chemistry and known DNA-reactive genotoxic 6 
carcinogenicity. It took several years to codify Ashby and Tennant’s structure-activity 7 
relationships computationally, but since then the ‘alerts’ have been expanded and 8 
defined.  9 
Structural alerts for DNA-reactive mutagenicity are effective for mechanisms 10 
that are based around electrophilic reactivity, i.e. compounds that will be positive in the 11 
Ames test. Such mechanisms are well defined from an organic chemistry point of view 12 
and can be readily captured (Enoch and Cronin 2010; Enoch and Cronin 2012). There 13 
are then a number of technologies to identify these structural alerts, the premise being 14 
that the presence of an alert in a molecule would indicate the potential for activity (e.g. 15 
Votano et al. 2004; Tropsha and Tropsha 2010). Currently technologies include 16 
commercial systems from the major software houses, to the use of open access systems. 17 
Whilst the process of defining an electrophilic fragment itself may be straightforward, a 18 
number of decisions need to be borne in mind when applying a fragment. The level of 19 
definition of an alert is important and they may be designed to be broad e.g. to identify 20 
any molecule with a specific functional group. Alternatively, the level of definition of 21 
an alert may be designed to be narrower, to take into account the ‘molecular 22 
environment’ e.g. other parts of the molecule that may decrease or increase activity. 23 
Broad alerts are useful for grouping and category formation – the OECD and OASIS 24 
DNA binding profilers are examples of these. Implicitly they are likely to be over-25 
predictive. Narrower, or more defined alerts, e.g. in DEREK Nexus are likely to be 1 
more applicable in hazard assessment.  2 
This in silico process of identification of structural alerts is an important 3 
consideration in the hazard identification of a compound with few data. However, it 4 
does not provide a quantitative threshold for toxicological concern and does not 5 
diminish the importance of reliable TTC values (Figure 1). It is always difficult to know 6 
which of the various types of software to utilise and there are no hard and fast rules. It 7 
must also be borne in mind that all in silico approaches, for making important decisions 8 
on individual chemicals, must be considered in context and on a chemical-by-chemical 9 
basis. One approach, e.g. ICH M7 for DNA-reactive mutagenic impurities (ICH 2014), 10 
has been to consider a rule-based (SAR) and statistical (QSAR) approach. For DNA-11 
reactive substances, it may be possible to refine this process. For instance, combination 12 
of a chemistry based profiler (e.g. the OECD profiler for DNA reactivity in the OECD 13 
QSAR Toolbox) with appropriate use of the rules for DNA reactivity from a knowledge 14 
based profiler (e.g. DEREK Nexus) may give complementary and increased coverage. 15 
QSAR models may be less applicable for the identification of directly DNA-reactive 16 
substances than structural alert based approaches as they are derived from statistical 17 
models utilising global, or general, molecular descriptors as opposed to predictions 18 
directly from known DNA-reactive fragments. However, they may again provide 19 
complementary information. Thus, there may be merit in considering the use of two 20 
types of structural alert approach, possibly in addition to a QSAR model. The 21 
disadvantage is the increased complexity of using the information from multiple 22 
models, e.g. how and when a consensus would be reached. This will be, in part, down to 23 
the user to decide how conservative they require the assessment to be.   24 
A further, critical, aspect to the application of structural alerts is that of 1 
metabolism and how this is included, or not, into the model. Alerts can be written to 2 
implicitly take account of metabolism, for instance, alerts for aromatic amines assume 3 
the metabolic steps that lead to the reactive nitrenium ion metabolite; thus it is not the 4 
parent compound itself that is genotoxic/mutagenic but the assumed metabolite. Other 5 
alerts do not assume the metabolic step. Thus, the metabolites themselves must be 6 
predicted and subsequently screened for structural alerts. Likewise, with SAR or 7 
statistical approaches, the metabolic step may be implicit. Whilst there are 8 
computational methods to predict metabolites (Kirchmair et al. 2015), they can predict a 9 
large number of metabolites, many of which are irrelevant(i.e. whilst they are 10 
theoretically possible they are not formed in biological systems),from which it can thus 11 
be difficult to identify those important for toxicity. Thus, metabolism must be 12 
considered in the hazard assessment of compounds that do not have a structural alert 13 
identified. The consideration of metabolism will inevitably affect the performance of 14 
the models and better consideration of how to include these effects, and those metabolic 15 
conversions most relevant for genotoxicity, is required. Thus, with the new, and 16 
refinements of existing, methods, there is a need to revisit this process to determine if 17 
the overall scheme and approach can be improved even further. 18 
A further issue to be noted with the use of structural alerts for DNA-reactive 19 
mutagenicity is the meaning of a ‘negative’ prediction. In other words, if a compound 20 
does not contain a structural alert, how much confidence is there that it is not a DNA-21 
reactive mutagen? This topic has stimulated much debate (Ellison et al. 2011). The 22 
reality is that it is widely acknowledged that predictions of DNA-reactive mutagenicity 23 
from structural alerts are likely to be more acceptable (from a precautionary 24 
perspective) than negative predictions.  Nevertheless, in their recent review of the TTC 25 
approach, EFSA and WHO concluded that negative predictions using appropriate 1 
software were acceptable in the application of the TTC approach (EFSA 2016) and the 2 
reliability of negative predictions is supported by a recent analysis by Williams et al. 3 
(2016). 4 
With regard to the practical application of structural alerts to identify DNA-5 
reactive mutagenic carcinogens, software can be freely available such as SMARTS 6 
(2016) and the chemoTyper(Altamira LLC; Yang et al. 2015), or associated with a cost 7 
e.g. requiring payment or on a commercial basis (e.g. DEREK Nexus). In addition, there 8 
are different philosophies in the derivation of rules, varying from direct mechanistic 9 
interpretation and toxicological expert knowledge (e.g. DEREK Nexus), to derivations 10 
from organic reaction mechanisms and chemistry (e.g. OECD DNA binding profiler), to 11 
machine learning approaches (e.g. MultiCASE). The compilations of alerts that are 12 
freely available are summarised in Table 2. The most comprehensive of these is 13 
available in the OECD QSAR Toolbox (freely downloadable from 14 
http://www.qsartoolbox.org/). This comprises a number of profilers that can be applied 15 
to identify DNA-reactive mutagenic carcinogens, including those from the European 16 
Commission’s Joint Research Centre’s ToxTree software and United States 17 
Environmental Protection Agency’s Oncologic software. At this time, however, there is 18 
no coherent strategy on how to apply all these profilers and it should be borne in mind 19 
that the purpose of the OECD QSAR Toolbox is primarily to facilitate grouping and not 20 
to identify hazard. The commercial software to predict mutagenicity from structural 21 
knowledge is summarised in Table 3. In addition, there are a number of techniques 22 
which can be thought of as being ‘hybrid’ (a mixture of structural alerts and models), or 23 
statistically derived QSARs, and these are summarised in Table 4. 24 
Discussion 1 
The TTC approach was recently reviewed at an Expert Workshop organised by EFSA 2 
and the WHO (EFSA 2016). At that meeting, whilst evidence supporting the non-cancer 3 
TTC values was reviewed, and proposals for improvement were made, with respect to 4 
the cancer TTC value it was concluded that: 5 
‘Expanding the TTC cancer dataset (e.g. with the ToxRef database) would enhance 6 
the power and range of chemical structures covered. However, this is not 7 
considered a priority as it would be resource demanding and is not expected to 8 
significantly affect the approach.’ 9 
‘If a revision of the carcinogenicity/genotoxicity based TTC were to be envisaged, 10 
it is recommended considering approaches other than TD50-based linear 11 
extrapolation from the most sensitive species and most sensitive site, which may be 12 
overly conservative.’ 13 
Hence, reanalysis of the appropriateness of the TTC value for DNA-reactive mutagenic 14 
carcinogens as outlined in this document would add to the confidence in the overall 15 
TTC approach.  16 
Rigorous, transparent basis for TTC value for compounds that are DNA-17 
reactive mutagenic carcinogens 18 
The derivation of a TTC value for compounds that are DNA-reactive mutagenic 19 
carcinogens is currently not as transparent as for the other TTC values in current use in 20 
the TTC decision trees of organisations such as the WHO and EFSA. Whereas the latter 21 
are based on distributional analyses of publicly accessible databases, the former is based 22 
on a hybrid approach, difficult to follow and document (e.g. Kroes et al. 2004). The 23 
database on which this TTC value is based comprises carcinogens with a range of 24 
modes of action, human relevance and quantitative outcomes in rodent bioassays. Re-25 
analysis of the database, with expansion if possible, according to the criteria outlined in 26 
the current manuscript would provide a much more transparent and rigorous basis for 1 
derivation of this TTC value. 2 
Appropriateness of non-genotoxic TTC values for compounds that might be 3 
carcinogenic by another MOA 4 
It is implicit in the TTC approach that any compound that is not captured by the lowest 5 
TTC value would be covered by the higher TTC values in the decision tree. Most often 6 
this would be 1.5 µg/kg bw per day or higher (unless the compound has a structure 7 
suggesting inhibition of acetylcholinesterase activity). Yet, carcinogenicity, per se, is 8 
not reliably predictable on the basis of structure alone. Hence, it has to be assumed that 9 
any compound that is carcinogenic by a MOA other than DNA-reactive mutagenicity, 10 
will be adequately covered by these higher TTC values. As discussed above, there is 11 
evidence that this would be the case, at least for the current TTC value for DNA-12 
reactive mutagenic carcinogens. However, detailed analysis as described above would 13 
enable robust conclusions to be reached on a) what is the level of protection provided by 14 
the higher TTC values for carcinogens acting by a non-genotoxic MOA and b) how 15 
does this compare with any revised TTC value for DNA-reactive mutagenic 16 
carcinogens. 17 
Reliability/protectiveness of use of structural alerts for DNA-reactive mutagens 18 
Axiomatic in this approach is the ability to identify those compounds likely to be DNA-19 
reactive mutagens. As discussed above, rigorous evaluation of the original data on 20 
genotoxicity, and application of a robust weight-of-evidence approach, will provide a 21 
more reliable dataset on not only the genotoxicity of the compounds in the database but 22 
also on the MOA for their genotoxicity. In addition, assessment of likelihood of in vivo 23 
genotoxicity will be invaluable in such analyses. This information will enable a detailed 24 
evaluation of the reliability and suitability of different software packages in identifying 1 
those compounds of most concern with respect to the TTC value for DNA-reactive 2 
mutagenic carcinogens. Also, as described in section on “Identification of 'relevant' 3 
genotoxins using structural alerts”, the in silico techniques used may utilise different 4 
approaches e.g. chemistry and knowledge derived structural alerts and QSAR models. A 5 
well curated database is essential to determine the performance of such models. The 6 
accuracy of the structural alerts and QSAR models, either individually or through 7 
weight-of-evidence or consensus, can be compared with both the genotoxicity and the 8 
carcinogenicity data, enabling conclusions to be reached on which software packages 9 
are most suitable for application in the TTC approach. This may also highlight well 10 
performing (in terms of protectiveness) alerts and provide insight into the role of 11 
metabolism. Their level of protection can be calculated based on the false positive and 12 
false negative rates. 13 
More detailed analysis could reveal structural alerts that do not contribute 14 
meaningfully to the overall conclusions and hence could lead to revision of the software 15 
for use in TTC applications. 16 
Possibility of including structural alerts for other cancer MOAs 17 
Initiatives such as the WHO Mode of Action for Chemical Carcinogens and Human 18 
Relevance, the OECD Adverse Outcome Pathways (AOP) database and the National 19 
Institute of Environmental Health Sciences (NIEHS) Hallmarks of Cancer are leading to 20 
the identification of early key events, including molecular initiating events (MIEs) that 21 
are causally related to the carcinogenicity of chemicals, by a variety of both genotoxic 22 
and non-genotoxic modes of action. When the primary molecular interaction is known 23 
(the MIE), it is likely that structural or other physiochemical predictors will be 24 
established and that these can be used as alerts for such modes of action. A database 25 
constructed as described above should enable the utility of some such alerts to be 1 
evaluated and perhaps ultimately to be included in a revised TTC decision tree. 2 
However, the benefit of this should be judged against the relative level of protection 3 
provided compared to that obtained using the existing TTC values.  4 
Reflections on COC 5 
In applying the TTC approach, a number of compounds are excluded, a priori, based on 6 
their membership of specific structural groups, e.g. aflatoxins, nitrosamines. These have 7 
been termed the cohort of concern and they are excluded because some members of the 8 
respective groups are such potent carcinogens that even the TTC for DNA-reactive 9 
mutagenic carcinogens would not be sufficiently protective and a value low enough to 10 
be protective would be of no practical value. However, detailed evaluation of the 11 
carcinogenicity, dose-response data and species differences of such compounds as 12 
envisaged above would enable their exclusion to be reassessed. For those classes where 13 
continuing exclusion was considered appropriate, the possibility of a group-specific 14 
TTC could be assessed.  15 
Potential applications of such a database beyond re-evaluation of TTC values 16 
The availability of an up-to-date, high quality, fully populated, curated, publicly 17 
available database of the nature envisaged above would have potential application well 18 
beyond re-evaluation of the TTC value for DNA-reactive mutagenic carcinogens. 19 
Obvious areas of application are the development of predictive algorithms for various 20 
types of genotoxicity and for carcinogenicity by a number of non-genotoxic modes of 21 
action. The information in the database should prove of value in developing AOPs for a 22 
variety of chemicals, for a number of endpoints in addition to cancer, given that 23 
information on non-cancer precursor effects will be included as appropriate. The 24 
database may also be of value in addressing the appropriateness or revision of 1 
adjustments of the TTC value for less-then-lifetime exposures, e.g. as is current practice 2 
for DNA-reactive mutagenicimpurities in human pharmaceuticals (ICH 2014), although 3 
this might require expanding the database with information from studies of relevant 4 
duration for such an analysis. 5 
Recommendations for depositing and maintaining database 6 
Clearly, for the database to fulfil its full potential, it would have to be maintained well 7 
beyond the lifetime of the TTC re-evaluation. Ideally, it would be deposited on a 8 
reliable, publicly accessible site, hosted by an organisation that would ensure at least 9 
technical maintenance, i.e. continuing accessibility. There are a number of such sites 10 
potentially suitable, such as the OECD, the eChem portal of the EU and various 11 
initiatives arising out of the US EPA CompTox program. Ideally, once deposited, the 12 
database would continue to be extended by addition of new information on chemicals 13 
already listed and by the addition of new chemicals. Some mechanism for quality 14 
control and data curation would need to be established. Given the public interest in the 15 
TTC approach and non-animal methods in general, it is to be hoped that support of the 16 
maintenance of such a database would be forthcoming from government and/or supra-17 
national bodies involved in chemical risk assessment. 18 
Next steps 19 
Basedon the foregoing, there is a strong argument for updating the CPDB based on the 20 
current state of knowledge and to use this as the basis for re-assessment of the TTC 21 
value for substances that are likely to be DNA-reactive mutagens, based on their 22 
chemical structure. Such an analysis would provide similar transparency and confidence 23 
to this TTC value as now exists for the other TTC values used in the decision tree 24 
developed by EFSA and the WHO (EFSA 2016). The analyses proposed would also 1 
establish the minimum level of protection provided by the existing TTC values for 2 
substances that are not likely to be DNA-reactive mutagens, and hence pass the first 3 
step of the decision tree, but may prove to be carcinogenic by some other MOA, i.e. that 4 
progress to step 4 of Fig 1. Finally, retrospective application of software tools for the 5 
identification of likely DNA-reactive mutagens to the substances in the dataset used for 6 
the reassessment of these TTC values would enable the robustness of the strategy used 7 
for step 2 of the decision tree (Fig. 1) to be determined, and enable specific 8 
recommendations to be made with respect to software tools and approaches for this 9 
purpose. 10 
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Table 1. Genotoxicity profiles of Ames-positive carcinogens (taken from the approaches 1 
used in compiling the database of Kirkland et al. (2014) that are considered the 2 
strongest candidates to exert a genotoxic mode of action for carcinogenicity in 3 
descending order of confidence (Group1 strongest, Group 6 weakest evidence).In vivo 4 
effects in the target tissue (and target species) for carcinogenicity would carry particular 5 
weight. 6 
Group In vivo 
mammalian 
mutation 
In vivo 
mammalian 
cytogenicity 
In vivo 
mammalian 
UDSa or 
comet 
 In vitro 
mammalian 
cell mutation 
In vitro 
mammalian 
cell 
cytogenicity 
1 
 
 
+ + + or NAa  + + 
+ + or NA +  + + 
+ or NA + +  + + 
       
2 + + + or NA  + NA 
+ + or NA +  + NA 
+ or NA + +  + NA 
+ + + or NA  NA + 
+ + or NA +  NA + 
+ or NA + +  NA + 
       
3 + + + or NA  NA NA 
+ + or NA +  NA NA 
+ or NA + +  NA NA 
       
4 + NA NA  + + 
NA + NA  + + 
NA NA +  + + 
       
5 + NA NA  + NA 
+ NA NA   NA + 
NA + NA  + NA 
NA + NA  NA + 
NA NA +c  + NA 
NA NA +c  NA + 
       
6 + NA NA  NA NA 
NA + NA  NA NA 
NA NA +c  NA NA 
+ Evidence of genotoxicity using accepted criteria for the test  1 
a Some chemicals that gave negative results in liver UDS tests but were positive in the in vivo 2 
comet assay were included since the liver UDS test has been shown to be insensitive to a 3 
number of carcinogens (Kirkland and Speit 2008) 4 
b NA: Result not available, i.e. test was not performed 5 
c Care should be taken to evaluate the quality and source of the data if the only in vivo positive 6 
result is in a comet assay 7 
 8 
9 
Table 2.A summary of freely available sets of rules, or profilers, which may be used to 1 
identify genotoxic carcinogens from the OECD QSAR Toolbox. 2 
Profiler / Rulebase Details Reference, if 
applicable 
Protein binding 
alerts for 
chromosomal 
aberration by 
OASIS v1.1 
 
28 structural alerts accounting for 
interactions of chemicals with specific 
proteins, such as topoisomerases, 
cellular protein adducts, etc. The scope 
of this profiler is to investigate the 
ability of target molecules to elicit 
clastogenicity and aneugenicity 
Mekenyan et al. 2007 
DNA binding by 
OASIS v.1.3 
Ames mutagenicity model (part of the 
OASIS TIMES system – see Table 3) 
with 78 structural alerts for interaction 
with DNA 
Mekenyan et al. 2004; 
Serafimova et al. 2007 
 
DNA binding by 
OECD 
 
60 mechanistic organic chemistry 
fragments (in the form of structural 
alerts) for the binding of organic 
compounds to DNA. 
Enoch and Cronin 
2010; Enoch and 
Cronin 2012 
Carcinogenicity 
(genotox and 
nongenotox) alerts 
by ISS 
 
A decision tree for estimating 
carcinogenicity, based on a list of 55 
structural alerts (SAs). Of the alerts, 35 
derive from the Toxtree module and 20 
were derived separately. Most of the 
new SAs are relative to non- genotoxic 
 
carcinogenicity, whereas the SAs in the 
initial list mainly coded genotoxic 
carcinogenicity 
in vitro 
mutagenicity 
(Ames test) alerts 
by ISS 
Mutagenicity/Carcinogenicity module 
from Toxtree comprising a list of 30 
structural alerts (SAs). 
 
 
in vivo 
mutagenicity 
(micronucleus) 
alerts by ISS 
 
ToxMicrulebase from the Toxtree 
software comprising 35 structural alerts 
(SAs) for a preliminary screening of 
potentially in vivo mutagens.  
 
OncoLogic Primary 
Classifier 
Molecular definitions developed to 
mimic the structural criteria of 
chemical classes of potential 
carcinogens covered by the U.S. 
Environmental Protection Agency’s 
OncoLogic™ Cancer Expert System 
for Predicting the Carcinogenicity 
Potential 
 
ChemoTyper 
(Altamira/ 
Molecular 
Networks) 
Ashby Tennant genotoxic carcinogenic 
rules implemented in ChemTyper. This 
tool was implemented by a contract 
from US FDA CFSAN. 
Ashby and Tennant 
1991; Ashby 1994; 
Yang et al. 2015 
 1 
Table 3.A summary of commercially available expert systems based on structural alerts 1 
for the identification of genotoxic carcinogens. 2 
System and 
Supplier 
Endpoint Reference / Link 
DEREK Nexus from 
Lhasa Ltd  
Various rulebases for mutagenicity 
including bacterial ….. in vitro 
cytogenicity in mammalian cells, in vitro 
micronucleus studies  
https://www.lhasalimited.
org/derek_nexus/ 
 
ToxAlert, 
HazardExpert 
(CompuDrug) 
Mutagenicity  http://www.compudrug.co
m/ 
 
Case Ultra 
MultiCASE 
Mutagenicity  http://www.multicase.co
m/ 
 
Genetox Expert 
Alerts Suite 
(Leadscope) 
Genetic Toxicity http://www.leadscope.co
m/genetox_expert_alerts/ 
ChemTunesToxGPS 
(Molecular 
Networks/Altamira) 
Rule-base for mutagenicity, in vitro 
chromosome aberration, and 
micronucleus (WOE prediction) 
https://www.mn-
am.com/products/chemtu
nes_studio 
 3 
4 
Table 4.A summary of computational systems to predict mutagenicity and related 1 
endpoints based on SAR, QSAR or hybrid systems. 2 
System and 
Supplier 
Endpoint(s) Type of systems Reference / Link 
ToxRead (Mario 
Negri Institute, 
Milan, Italy) 
Ames 
mutagenicity 
QSAR (chemical 
similarity) – freely 
available 
http://www.toxgate.eu/ 
VEGA (Mario 
NegriInstitute, 
Milan, Italy) 
Ames 
mutagenicity 
Hybrid (ToxTree) 
rules and QSAR – 
freely available 
http://www.vega-qsar.eu/ 
Lazar  
 
Ames 
mutagenicity 
QSAR – freely 
available 
http://lazar.in-silico.de 
 
Toxicity Estimation 
Software Tool 
(TEST) (US EPA) 
Ames 
mutagenicity 
QSAR – freely 
available 
https://www.epa.gov/che
mical-research/toxicity-
estimation-software-tool-
test 
Tox Suite (ACD 
Labs) 
Ames 
mutagenicity 
QSAR - commercial http://www.acdlabs.com/p
roducts/pc_admet/tox/tox/ 
Non-human Genetic 
Toxicity Suite 
(Leadscope) 
Salmonella 
andE. coli 
mutagenicity,  
mouse 
lymphoma, in 
vitro 
chromosome 
QSAR - commercial http://www.leadscope.co
m/genetic_toxicity_suite/ 
 
 
aberrations, in 
vivo 
micronucleus 
Multicase 
MCASE/MC4PC 
(MultiCASEInc)  
Many endpoints 
relating to 
mutagenicity 
and genotoxicity  
QSAR - commercial http://www.multicase.co
m/ 
 
OASIS-TIMES 
(Laboratory of 
Mathematical 
Chemistry, Bourgas 
University)  
mutagenicity, 
chromosomal 
aberrations and 
micronucleus 
formation 
including 
metabolism 
prediction 
Hybrid rules and 
QSAR - commercial 
http://oasis-
lmc.org/?section=softwar
e&swid=4 
 
PASS (Institute of 
Biomedical 
Chemistry of the 
Russian Academy of 
Medical Sciences) 
 
Various 
mutagenicity 
Hybrid rules and 
QSAR - commercial 
http://www.pharmaexpert.
ru/PASSOnline/  
MolCode Toolbox Mutagenicity QSAR - commercial http://molcode.com/ 
 
OpenTox Micronucleus QSAR – freely 
available 
http://apps.ideaconsult.net
:8080/ToxPredict 
 TOPKAT 
(Accelrys)  
 
Ames 
mutagenicity  
QSAR - commercial http://accelrys.com/produ
cts/collaborative-
science/biovia-discovery-
studio/qsar-admet-and-
predictive-
toxicology.html 
ChemTunesToxGPS 
(Molecular 
Networks/Altamira) 
Ames  
Mutagenicity; in 
vitro 
chromosome 
aberration; in 
vivo 
micronucleus 
QSAR (WOE 
prediction) – 
commercial  
 
https://www.mn-
am.com/products/chemtu
nes_studio  
Sarah Nexus (Lhasa 
Ltd) 
Mutagenicity QSAR – commercial  Hanser et al. 2014 
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Figure 1.Tiers of the TTC concept as described in the WHO EFSA Report 2016 (EFSA, 2 
2016). For explanation of the “exclusionary categories” see section on “Outline of 3 
current TTC scheme”. The green broken-line boxes indicate where a conclusion on the 4 
acceptability of estimated human exposure can be reached. The red broken-line boxes 5 
indicate where safety at estimated human exposure cannot be assured and further 6 
information would be necessary to enable completion of the assessment. 7 
